Prognostic Value of the HALP Score in Metastatic Mesothelioma: A Retrospective Study.

IF 1.8 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2025-07-08 DOI:10.1159/000547271

Ozlem Dogan, Yakup Duzkopru, Tulay Eren

{"title":"Prognostic Value of the HALP Score in Metastatic Mesothelioma: A Retrospective Study.","authors":"Ozlem Dogan, Yakup Duzkopru, Tulay Eren","doi":"10.1159/000547271","DOIUrl":null,"url":null,"abstract":"Background: Malignant mesothelioma is a rare but aggressive cancer with limited treatment options and poor prognosis. Hemoglobin, Albumin, Lymphocyte, Platelet(HALP) score , reflecting inflammation and nutritional status, is a potential prognostic marker in various cancers. Our study aims to investigate the prognostic value of the HALP score in mesothelioma.Methods: This retrospective study included 68 metastatic mesothelioma patients diagnosed between 2015-2023. Clinical and laboratory data were collected, and HALP scores were calculated at the time of metastasis. Patients were divided into HALP-low and HALP-high groups based on the median HALP score. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method, and prognostic factors were assessed using univariate and multivariate analyses.Results: The median HALP score was 24.85. The median OS for the entire cohort was 11,59 months. Patients with low HALP scores had significantly worse OS (7,81 months) compared to those with high HALP scores (16,36 months) (p=0.01). Similarly, median PFS was significantly shorter in the HALP-low group (7,29 months) compared to the HALP-high group (12,12 months) (p=0.02). In multivariate analysis, low HALP score (p=0.02) and de novo metastatic disease (p=0.01) remained independent prognostic factors for OS.Conclusion: This study demonstrates that the HALP score is an independent prognostic biomarker in metastatic mesothelioma. Low HALP scores are associated with worse OS and PFS. Given its simplicity and cost-effectiveness, the HALP score may be a valuable tool for risk stratification and treatment decision-making in clinical practice.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-14"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547271","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Malignant mesothelioma is a rare but aggressive cancer with limited treatment options and poor prognosis. Hemoglobin, Albumin, Lymphocyte, Platelet(HALP) score , reflecting inflammation and nutritional status, is a potential prognostic marker in various cancers. Our study aims to investigate the prognostic value of the HALP score in mesothelioma.

Methods: This retrospective study included 68 metastatic mesothelioma patients diagnosed between 2015-2023. Clinical and laboratory data were collected, and HALP scores were calculated at the time of metastasis. Patients were divided into HALP-low and HALP-high groups based on the median HALP score. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method, and prognostic factors were assessed using univariate and multivariate analyses.

Results: The median HALP score was 24.85. The median OS for the entire cohort was 11,59 months. Patients with low HALP scores had significantly worse OS (7,81 months) compared to those with high HALP scores (16,36 months) (p=0.01). Similarly, median PFS was significantly shorter in the HALP-low group (7,29 months) compared to the HALP-high group (12,12 months) (p=0.02). In multivariate analysis, low HALP score (p=0.02) and de novo metastatic disease (p=0.01) remained independent prognostic factors for OS.

Conclusion: This study demonstrates that the HALP score is an independent prognostic biomarker in metastatic mesothelioma. Low HALP scores are associated with worse OS and PFS. Given its simplicity and cost-effectiveness, the HALP score may be a valuable tool for risk stratification and treatment decision-making in clinical practice.

查看原文本刊更多论文

HALP评分对转移性间皮瘤的预后价值：一项回顾性研究。

背景：恶性间皮瘤是一种罕见但侵袭性的癌症，治疗方案有限且预后差。血红蛋白、白蛋白、淋巴细胞、血小板（HALP）评分反映炎症和营养状况，是多种癌症的潜在预后指标。我们的研究旨在探讨HALP评分在间皮瘤中的预后价值。方法：本回顾性研究纳入2015-2023年间诊断的68例转移性间皮瘤患者。收集临床和实验室资料，并在转移时计算HALP评分。根据中位HALP评分将患者分为低HALP组和高HALP组。采用Kaplan-Meier法分析总生存期（OS）和无进展生存期（PFS），采用单因素和多因素分析评估预后因素。结果：HALP评分中位数为24.85。整个队列的中位生存期为11.59个月。低HALP评分患者的OS（7、81个月）明显差于高HALP评分患者（16、36个月）（p=0.01）。同样，低halp组的中位PFS（7,29个月）明显短于高halp组（12,12个月）（p=0.02）。在多因素分析中，低HALP评分（p=0.02）和新发转移性疾病（p=0.01）仍然是OS的独立预后因素。结论：本研究表明，HALP评分是转移性间皮瘤的独立预后生物标志物。低HALP评分与较差的OS和PFS相关。由于其简单和成本效益，HALP评分可能是临床实践中风险分层和治疗决策的有价值的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.